828.65 2.45 (0.30%)
NSEJan 27, 2021 03:55 PM
The 18 reports from 5 analysts offering long term price targets for Relaxo Footwears Ltd. have an average target of 796.20. The consensus estimate represents a downside of -3.92% from the last price of 828.65.
|Summary||Date||Stock||Broker||Price at Reco.||Target||Price at reco|
Change since reco(%)
|2020-12-21||Relaxo Footwears Ltd. +||Axis Direct||766.85||925.00||766.85 (8.06%)||Target met||Buy|
|2020-12-18||Relaxo Footwears Ltd. +||Axis Direct||786.75||816.00||786.75 (5.33%)||Target met||Buy|
|2020-11-03||Relaxo Footwears Ltd. +||Axis Direct||685.85||747.00||685.85 (20.82%)||Target met||Buy|
Relaxo Footwear(RLXF) for Q2FY21 reported revenue at Rs. 576 cr on the back of 2% volume growth (22.5% above our estimates) as compared to Rs. 622 cr in the corresponding quarter of the previous year, 7.4% lower YoY.
|2020-11-03||Relaxo Footwears Ltd. +||Karvy||685.85||710.00||685.85 (20.82%)||Target met||Hold|
Gross Margins - A Positive Surprise: Revenue for Q2FY21 was 7.4percent lower on YoY basis but EBITDA was up significantly,at 21.2percent on account of higher gross margins and good cost control measures.Gross margins were higher by 505 bps on account of lower inventory, tradedgoods and commodity prices.
|2020-11-03||Relaxo Footwears Ltd. +||ICICI Securities Limited||685.85||765.00||685.85 (20.82%)||Target met||Buy|
ICICI Securities Limited
As most people are working from home, sales of sandals, flip flops have seen a significant surge in demand. Relaxo being a dominant player in the aforesaid categories, through its strong portfolio of brands (Flite', Bahamas', Hawaii') has witnessed a swift recovery in volumes and captured market share from unorganised players in H1FY21. While sale of shoes continues to be laggards (sports, canvas), green shoots are visible with gradual opening up of the economy. Further, on festive demand trends, healthy traction has been seen in October in most regions except Kerala....
|2020-11-02||Relaxo Footwears Ltd. +||Axis Direct||664.35||728.00||664.35 (24.73%)||Target met||Buy|
|2020-08-27||Relaxo Footwears Ltd. +||Dolat Capital||639.85||651.00||639.85 (29.51%)||Target met||Buy|
Plan to set up new manufacturing plant at Bhiwadi To cater to the growing demand, the company has commenced commercial production at its new plant at Bhiwadi (Rajasthan) for manufacturing flip flops (Hawaii range). It has proposed to add capacity of 100K pairs/day in Bhiwadi plant with total investment of Rs 900mn which will be funded through internal accruals. The capacity will be added within three years and is likely to take Relaxo's total capacity to 800K pairs/day...
|2020-08-08||Relaxo Footwears Ltd. +||Karvy||637.20||718.00||637.20 (30.05%)||Target met||Hold|
Outlook and Valuation: We continue to bank on Relaxo in the medium to long term as the best placed stock in the space on account of a good rural and urban mix and excellent track record of the management, coupled with good financial stability.
|2020-08-04||Relaxo Footwears Ltd. +||Axis Direct||613.75||697.00||613.75 (35.01%)||Target met||Buy|
Disruption owing to nationwide lockdown till first week of May and significant disturbances during remaining period led to contraction of revenue and gross margins for Relaxo Footwear in Q1FY21. Revenue for the quarter de-grew by 43.9% YoY to Rs 363.6 cr
|2020-08-02||Relaxo Footwears Ltd. +||ICICI Securities Limited||595.20||715.00||595.20 (39.22%)||Target met||Buy|
ICICI Securities Limited
Relaxo Footwears has a strong portfolio of brands (Sparx', Flite', Bahamas') that mainly cater to the mass segment (ASP ~| 139). Around two-third of revenues are derived from slippers/open sandals (non-discretionary in nature) while rest are through premium affordable sports shoes. Hence, it has seen better traction in revenue recovery. The company is likely to enhance its focus on value products rather than premium products in the next two quarters. Relaxo has, over the years, established a healthy distribution network, with 800+ distributors catering to ~50000 retailers....
|2020-07-15||Relaxo Footwears Ltd. +||Axis Direct||621.60||697.00||621.60 (33.31%)||Target met||Buy|
The footwear players in the industry are moving towards premium categories whereas Relaxo over the year has focused on the mass and value category footwear where competition from other branded players is low. We, Initiate coverage with BUY rating on the stock with a target price of Rs 697.
|2020-06-29||Relaxo Footwears Ltd. +||Karvy||631.75||737.00||631.75 (31.17%)||Target met||Buy|
|2020-06-09||Relaxo Footwears Ltd. +||ICICI Securities Limited||659.95||715.00||659.95 (25.56%)||Target met||Hold|
ICICI Securities Limited
Relaxo exited FY20 with revenue growth of 5% YoY to | 540.6 crore. Topline was mainly driven by realisation growth of 8% YoY to | 135/pair. Volumes for FY20 fell 2.7% YoY to 17.9 crore pairs (management indicated volume growth till mid-March was at 6-7%). Favourable product mix and benign raw material prices resulted in gross margin expansion of 370 bps YoY to 56.9%. Subsequently, EBITDA margins improved 170 bps YoY to 15.7% (adjusted for Ind-AS 116). The management indicated that while north, east and central regions have gradually picked up pace, western region continues to...
|2020-06-08||Relaxo Footwears Ltd. +||Sharekhan||674.55||825.00||674.55 (22.84%)||Target met||Buy|
Relaxo Footwears Limited (Relaxo) posted mixed numbers in Q4FY2020 with revenues declining by 15% y-o-y (affected by lockdown) but higher gross margins leading to a 282 bps rise in reported OPM to 17.8% (comparable OPM improved by ~70 bps to 15.7%). FY2020 revenues grew by 5.2%y-o-y affected by lockdown in the fag end of Q4FY2020 (9MFY2020 revenue grew by 12.9%). Volumes declined by 2.7% in FY2020 affected by a lockdown in the last 1015 days of March and higher sales of premium products (~20% of overall revenues). Q1FY2021 performance would be affected by no sales during the lockdown period. Gradual opening of lockdown would help in recovery in...
|2020-06-08||Relaxo Footwears Ltd. +||Dolat Capital||674.55||773.00||674.55 (22.84%)||Target met||Buy|
Revenue declined 15% YoY to Rs 5.4bn in Q4FY20 - came below our estimate. Nationwide lockdown resulted in drop in revenues. Sharp fall in volumes was partially offset by price hikes implemented prelockdown period. Further price hikes would depend on the demand scenario. We believe that the margins would remain high considering larger contribution of distribution business compared to retail business. In the long run, we believe that the company would continue its strong performance by increasing penetration in South and West and is likely to further benefit from premiumization. Relaxo should continue to outpace...
|2020-03-13||Relaxo Footwears Ltd. +||ICICI Securities Limited||639.45||775.00||639.45 (29.59%)||Target met||Buy|
|2020-02-04||Relaxo Footwears Ltd. +||Karvy||752.15||809.00||752.15 (10.17%)||Target met||Hold|
|2019-11-13||Relaxo Footwears Ltd. +||Karvy||550.35||638.00||550.35 (50.57%)||Target met||Buy|
|2019-11-05||Relaxo Footwears Ltd. +||Sharekhan||570.80||650.00||570.80 (45.17%)||Target met||Buy|
Relaxo Footwears' (Relaxo's) Q2FY2020 reported numbers are not comparable y-o-y due to implementation of Ind-AS 116. Revenue grew by 14.5% y-o-y driven by premiumisation and price hikes, while reported PAT grew by ~79% y-o-y helped by strong operating performance and a lower corporate tax rate. Implementation of Ind-AS 116 impacted profit before tax by Rs. 2.1 crore. Relaxo reported resilient performance amid slow discretionary environment and going ahead, its operating performance is likely to remain steady, backed by sustained volume...
|2019-11-05||Relaxo Footwears Ltd. +||Dolat Capital||570.80||635.00||570.80 (45.17%)||Target met||Buy|